Christina Kalderén, Preclinical Director and Sandra Ekstedt, Senior Scientist will present two posters at the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF), in Athens 12 – 16 October 2024:
“OXC-201, an OGG1 Inhibitor for IPF Clinical Translation: Harnessing a Combination of In Vivo & In Vitro Models to Create an Effective Preclinical Package”
“Inhibition of OGG1 – a new approach for IPF treatment. OXC-201 antifibrotic effects in lung fibroblasts compared to clinical pipeline and standard pf care”
Find out more about the meeting and join Christina and Sandra to connect with the lung fibrosis community sharing insights to develop effective therapies faster: Homepage – ICLAF
Briefly about OXC-201
OXC-201 is a small molecule inhibitor of OGG1, a potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), other fibrotic conditions and inflammatory diseases. By targeting the DNA repair enzyme OGG1 (8-oxo guanine DNA glycosylase-1), OXC-201 inhibits binding of OGG1 to DNA and thereby the modulation of gene transcription. OGG1 plays a significant role in modulating inflammation and fibrogenesis; genetic downregulation or chemical inhibition of OGG1 has been shown to protect against inflammation and fibrosis in several experimental disease models. OXC-201 is patent protected and Oxcia AB has exclusive rights under the patent to develop and commercialize OXC-201.
The EIC (European Innovation Council) has awarded Oxcia AB a grant of 2.5 million euros for the project TOPFIBRO within the EIC-Transition program. This finances the next phase of the development of OXC-201. More information is available at https://topfibro.oxcia.eu/
For more information, please contact:
Christina Kalderén, Pre-clinical Director
Email: christina.kalderen@oxcia.com
Or:
Ulrika Warpman Berglund, CEO
Email: ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia
Oxcia AB conducts innovative research through its unique way of utilizing oxidative DNA damage and DNA Damage response(1) and develops novel, safe and effective treatments for patients suffering from cancer, inflammation or fibrosis. Oxcia currently has two drug candidates, both with first-in-class potential. OXC-101 is in early clinical development for the treatment of solid and hematological cancers. OXC-201 is being developed as a treatment for inflammation and fibrosis-related diseases and is in the preclinical phase.
More information about Oxcia is available at www.oxcia.com
(Note (1): DNA Damage Response, DDR – the body's processes to in various ways repair the damage that occurs to DNA)